Trabalhos publicados sobre a Leishmune
Complementar Fase I.pdf
Haemolytic activities of plant saponins and adjuvants.pdf
Inhibition of Leishmania donovani Promastigote Internalizati.pdf
Saponins IL12.pdf
Experimental murine Leishmania donovani infection (1994).pdf
IgG1-IgG2 antibody dichotomy (2003).pdf
Protective vaccination against murine visceral leishmaniasis.pdf
The FML vaccine (fucose-mannose ligand) protects hamsters fr.pdf
Vaccination of Balbc mice.pdf
Vaccination of Swiss Albino mice experimental visceral leish.pdf
A phase III trial of efficacy of the FML-vaccine.pdf
Leishmune vaccine blocks the transmission.pdf
Long lasting protection against canine kala-azar using the F.pdf
The FML-vaccine - A transmission blocking vaccine.pdf
Tradução - Leishmune vaccine blocks.pdf
Tradução - The FML-vaccine.pdf
Expert Review.pdf
Immunogenicity assay of the Leishmune.pdf
Safety trial using the Leishmune vaccine.pdf
Conjunctival Evaluation.pdf
Flow Citometry.pdf
Improving methods for epidemiological control .pdf
Nucleoside Hydrolase from Leishmania.pdf
Reflexões sobre diagnóstico da LVC.pdf
The Fucose-mannose LigandElisa in the diagnosis and prognosi.pdf
Folheto Leishmune.pdf
Bula Leishmune.pdf
Despite Leishvaccine and Leishmune trigger distinct immune p.pdf
Investigação De Ctenocephalides Felis Como Vetor De Leishman.pdf
IVIS Valéria Marçal.pdf
Leishmaniose Visceral chega às cidades Revista Fapesp Set 2.pdf
Leishmune vaccine The newest tool.pdf
Pulcherrimasaponin (Fase I complement).pdf
R. sanguineus e leishmania.pdf
T-cell-derived cytokines, nitric oxid production by.pdf
Vaccines for leishmaniasis in the fore coming 25 years.pdf
Visceral Leishmniasis in Brazil.pdf
Effective immunotherapy.pdf
Immunotherapy against experimental canine visceral leishmani.pdf
Immunotherapy against murine.pdf